Trials / Withdrawn
WithdrawnNCT04998747
A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 1b Open-label Study Evaluating the Safety and Pharmacokinetics of Subcutaneous AMG 701 for the Treatment of Relapsed or Refractory Multiple Myeloma (ProxiMMity-1)
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to evaluate the safety and tolerability of subcutaneous (SC) AMG 701 in participants with relapsed or refractory multiple myeloma (RRMM) to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 701 | AMG 701 will be administered as SC or intravenous injection. |
| DRUG | AMG 701 | AMG 701 will be administered as SC injection. |
Timeline
- Start date
- 2023-08-29
- Primary completion
- 2025-08-02
- Completion
- 2025-08-28
- First posted
- 2021-08-10
- Last updated
- 2022-09-27
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04998747. Inclusion in this directory is not an endorsement.